Zymeworks Inc
NASDAQ:ZYME
Zymeworks Inc
Net Income (Common)
Zymeworks Inc
Net Income (Common) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Zymeworks Inc
NASDAQ:ZYME
|
Net Income (Common)
-$113.7m
|
CAGR 3-Years
19%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
N/A
|
|
|
Abbvie Inc
NYSE:ABBV
|
Net Income (Common)
$4.2B
|
CAGR 3-Years
-28%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
9%
|
|
|
Gilead Sciences Inc
NASDAQ:GILD
|
Net Income (Common)
$480m
|
CAGR 3-Years
-57%
|
CAGR 5-Years
-38%
|
CAGR 10-Years
-28%
|
|
|
Amgen Inc
NASDAQ:AMGN
|
Net Income (Common)
$4.1B
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-12%
|
CAGR 10-Years
-2%
|
|
|
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
|
Net Income (Common)
-$535.6m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
3%
|
|
|
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
|
Net Income (Common)
$4.4B
|
CAGR 3-Years
-18%
|
CAGR 5-Years
16%
|
CAGR 10-Years
29%
|
|
Zymeworks Inc
Glance View
Zymeworks Inc. is a biopharmaceutical company. The company is headquartered in Middletown, Delaware and currently employs 286 full-time employees. The company went IPO on 2019-06-24. Its lead product candidate is zanidatamab, a bispecific antibody that targets two distinct domains of the human epidermal growth factor receptor 2 (HER2). Its product candidate ZW49, combines the design of zanidatamab with its ZymeLink ADC platform, comprised of its cytotoxin and cleavable linker. The firm operates through a number of platforms, including Azymetric, ZymeLink, EFECT and ProTECT. Its Azymetric is a bispecific platform that enables therapeutic antibodies to simultaneously bind multiple distinct locations on a target or to multiple targets. The Company’s ZymeLink is an antibody-drug conjugate (ADC) platform comprised of cytotoxins and the linker technology used to couple these cytotoxins to tumor-targeting antibodies or proteins.
See Also
What is Zymeworks Inc's Net Income (Common)?
Net Income (Common)
-113.7m
USD
Based on the financial report for Sep 30, 2024, Zymeworks Inc's Net Income (Common) amounts to -113.7m USD.
What is Zymeworks Inc's Net Income (Common) growth rate?
Net Income (Common) CAGR 5Y
-12%
The average annual Net Income (Common) growth rates for Zymeworks Inc have been 19% over the past three years , -12% over the past five years .
You don't have any saved screeners yet